OR9A4 inhibitors pertain to a class of chemical compounds designed to selectively bind to and inhibit the activity of a specific protein or receptor identified as OR9A4. The OR9A4 is one of the many olfactory receptors, which are part of a larger family of G-protein-coupled receptors (GPCRs). These receptors are known for their role in detecting volatile chemical compounds, which contribute to the sense of smell. Inhibitors targeting the OR9A4 receptor are synthesized to interact with this receptor's active site, effectively blocking its ability to bind with its natural ligands. The specificity of these inhibitors is crucial, as the olfactory receptor family consists of a vast array of receptors, each with unique ligand affinities. The design of OR9A4 inhibitors requires a deep understanding of the molecular structure and binding kinetics associated with the OR9A4 receptor to ensure that the interaction is both selective and efficacious, thus avoiding off-target effects that could arise from interacting with other receptors within the olfactory or GPCR families.
The discovery and development of OR9A4 inhibitors involve a combination of computational modeling, structure-activity relationship studies, and biochemical assays to fine-tune the inhibitor structure for optimal binding. These inhibitors can be small organic molecules, peptides, or other forms of ligands that have been engineered to fit into the binding pocket of the OR9A4 receptor. The chemical composition of these inhibitors is varied, often containing aromatic rings, heteroatoms, and various functional groups that allow for interactions such as hydrogen bonding, hydrophobic effects, and van der Waals forces within the binding site. The precise conformation of the inhibitors plays a significant role in their ability to prevent the receptor's normal operation without affecting the structural integrity or function of other closely related receptors. As a result, the development of OR9A4 inhibitors is a sophisticated process that requires iterative optimization to achieve high selectivity and proper binding characteristics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Zinc | 7440-66-6 | sc-213177 | 100 g | $47.00 | ||
Zinc ions can act as allosteric inhibitors of G protein-coupled receptors (GPCRs) like OR9A4 by binding to specific sites on the receptor that are essential for its proper functioning, leading to a decrease in its activity. | ||||||
Copper(II) sulfate | 7758-98-7 | sc-211133 sc-211133A sc-211133B | 100 g 500 g 1 kg | $45.00 $120.00 $185.00 | 3 | |
Copper can interact with thiol groups and histidine residues on GPCRs, potentially altering the conformation of OR9A4 and inhibiting its ability to respond to ligands. | ||||||
Methyl-β-cyclodextrin | 128446-36-6 | sc-215379A sc-215379 sc-215379C sc-215379B | 100 mg 1 g 10 g 5 g | $25.00 $65.00 $170.00 $110.00 | 19 | |
This compound extracts cholesterol from membranes, which can disrupt lipid rafts and thus inhibit the signaling and function of GPCRs like OR9A4 that may be localized within these specialized membrane domains. | ||||||
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $442.00 | 3 | |
PTX ADP-ribosylates Gαi proteins, preventing their interaction with GPCRs like OR9A4, which results in the inhibition of OR9A4-mediated signaling pathways. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin is known to interfere with the binding of ligands to GPCRs, which may prevent the activation of OR9A4 by its specific odorant ligands. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 5 g 100 g 250 g 1 kg 5 kg | $32.00 $66.00 $95.00 $188.00 $760.00 | 13 | |
Caffeine acts as an antagonist at adenosine receptors, which are GPCRs; this mechanism could theoretically extend to OR9A4, where caffeine might inhibit the receptor's activity by preventing ligand binding. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
Ketoconazole inhibits cytochrome P450 enzymes, which could reduce the synthesis of specific odorants that serve as ligands for OR9A4, indirectly decreasing its activity. | ||||||
Ivermectin | 70288-86-7 | sc-203609 sc-203609A | 100 mg 1 g | $56.00 $75.00 | 2 | |
Ivermectin has been shown to potentiate the opening of certain ion channels indirectly associated with GPCR activity, potentially modulating the signaling pathways of OR9A4. | ||||||